Held at the Karolinska Instituet, in Stockholm, Sweden, a recent Nobel Minisymposium, " Molecular Oncology From Bench to Bedside, " marked a very special event the celebration of George and Eva Klein s combined 160th birthdays. To honor this occasion, Volume 97 of Advances in Cancer Research brings together a collection of contributions by their former students, colleagues, and collaborators from the past fifty years dedicated to George and Eva Klein. Over a decade ago, the editors of ACR initiated a subdivision of the series called " Foundations in Cancer Research " to distinguish chapters that reflect extraordinary and historical developments in cancer research this volume of tributes honoring the Kleins bodies of work presented at the minisymposium are especially appropriate for the series and should serve as an important resource for future generations.

Lymphomas are lymphoid malignancies derived from B or T lymphocytes, and their study has been and still is paradigmatic for many aspects of cancer research. Lymphoma: Methods and Protocols presents and discusses key methods that are used in lymphoma research, partly specific for lymphoma research but often adaptable to the study of other cancers. By covering a broad variety of methods used in lymphoma research, this book will be of interest not only for hematologists, hematopathologists, and immunologists but also for scientists interested in other fields of cancer research as well as human genetics. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Versatile and cutting-edge, Lymphoma: Methods and Protocols serves researchers studying human physiology with the ultimate goal of understanding and controlling these often terrible diseases.

Target Discovery and Validation Reviews and Protocols, Volumes 1 and 2 review the most progressive and current methods for drug target discovery and validation. These volumes explore how recent improvement in understanding the molecular mechanisms of human pathology is impacting drug target discovery in the laboratory and in real therapeutics, specifically for cancers and autoimmune disorders.

Volume 1 focuses on novel and innovative techniques, and presents the most up-to-date protocols available for maximizing the likelihood of achieving target-selective inhibition in vivo while minimizing side effects. The profound impact of genomics, proteomics and bioinformatics on target discovery is explored, and specific attention is given to the role of transgenic and knockout animals in functional genomics and target validation. Cancer researchers will find tremendous value in the molecular classification of breast cancers and the review of protocols for tumor antigens and cancer vaccines. The methods and protocols collected here, all reviewed by leading scientists and clinicians, present the practical details necessary for translating the enormous discovery potential of the genome into real therapeutic products.

Volume 2 collects all the practical details required for efficient translation of discovered targets into real pharmaceutical drugs. Specific targets in cancers and autoimmunity are described and the potential of using siRNAs, antisense oligonucleotides and RNA aptamers in patients is reviewed. This volume explores the tremendous impact of the application of genotyping and gene expression profiling on the future of healthcare, and presents cutting-edge protocols to aid inbringing agents against specific targets closer to application in the clinic.

Collectively, these volumes provide a thorough review of the most cutting-edge methods available for each step in drug target identification, validation, and clinical application. For researchers, an understanding of available methods aids in the creation of innovative experiments in the laboratory, and the successful translation of target discovery to real therapeutics.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. A very special event the Nobel Minisymposium, "Molecular Oncology - From Bench to Bedside," held at the Karolinska Instituet, in Stockholm, Sweden, was marked the celebration of George and Eva Klein's combined 160th birthday. To honor this occasion, this 2nd of two volumes brings together contributions by their former students, colleagues and collaborators of the past fifty years into a volume of Advances in Cancer Research dedicated to George and Eva. Over a decade ago, a subdivision of ACR called "Foundations in Cancer Research" was initiated and the tributes honoring the Kleins' bodies of work presented at the minisymposium are especially appropriate for the series.

Leptomeningeal Metastases is intended to provide the reader with an overview of the state-of-the-art therapy for the cancer patient with leptomeningeal cancer with additional information on epidemiology, symptom management, new clinical trials, and current basic research in animal models for experimental therapies.

Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development of targeted therapy.

From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients.

This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing.

Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy.

This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach."

Breast Cancer: A New Era in Management provides a compendium of succinct analysis of the many facets involved in the present day management of the breast cancer patient. The text provides the clinician or student with basic foundational knowledge in the rapidly expanding areas of expertise that are required for both the diagnosis and treatment of the breast cancer patient. Each topic, whether diagnostic or therapeutic, is presented in a straightforward fashion incorporating as part of each topic a description of the historical clinical landmarks leading to the present day, their present day position in the care of the breast patient, and finally, an assessment of possible future application and adaptation in clinical practice. Emphasis is placed on clear and concise explanations of each topic presented in stepwise fashion from fundamental elements to the more complex. Breast Cancer: A New Era in Management will act as a ready reference for the practicing surgeon and students seeking practical information on a particular clinical topic or scenario.

This Recent Results in Cancer Research volume provides an up-to-date overview of the multidisciplinary management of locally confined rectal cancer as well as colorectal cancer with synchronous resectable liver metastases. The contents comprise the majority of the invited contributions from the Second St. Gallen EORTC Gastrointestinal Cancer Conference, held on 6-8 March 2014 in St. Gallen, Switzerland. Written by some of the world s leading experts in the imaging, endoscopy, pathology, molecular biology, surgery, radiotherapy and medical oncology of rectal cancer and liver metastases, the chapters offer a comprehensive view on the latest recommendations in diagnosis and multidisciplinary treatment. Every clinician involved in the care of patients with rectal cancer will find this book interesting and helpful."

The relationship between oncologists and their cancer patients is rapidly evolving. Oncologists and other cancer professionals master new anticancer and supportive treatment options, while working under increasing economic pressure and time constraints, and are often unprepared to deal with all the challenges of their new position in a therapeutic relationship with cancer patients and families. Good communication is as essential as are modern laboratory tests and sophisticated diagnostics to achieve the best clinical results. This book updates the evolution of truth-telling and communication patterns worldwide and offers insights into the recent trends and emerging challenges in communication with cancer patients and families. New Challenges in Communication with Cancer Patients is an invaluable resource to medical professionals, educators and patients in establishing a strong and effective partnership built on trust and mutual understanding.

Imaging in Oncology will serve as an up-to-date, attractive book of oncologic imaging for radiologists, oncologists, radiation therapists and others involved in oncologic care. This volume provides pertinent clinical and research information that underpins accurate interpretation and sensible use of cancer imaging. It reviews the role of established and upcoming techniques in plain radiography, ultrasound, CT, MR nuclear medicine, PET and PET/CT for oncologic imaging as well as image-guided intervention. The book also highlights new developments and advances in oncologic imaging. Imaging in Oncology will appeal to physicians in practice and in training and to all interested in oncologic imaging.

This book discusses emerging nanotechnology-based tools that have the potential to dramatically impact cancer research, diagnostics, and treatment. Cancer is a complex, devastating, and debilitating disease and, although much progress has been made, novel, more effective diagnostic and treatment options are still needed, especially for advanced cancers. The ultimate goal is to detect cancer early and non-invasively and to provide efficacious and targeted precision treatments that cause fewer harmful side effects. This book explains how nanotechnology can exploit the size-, shape-, and composition-dependent properties of nanomaterials to provide novel tools for precision cancer medicine. It will be of interest to researchers and professionals working in the fields of chemistry, biology, materials science and engineering, and medicine who want to learn more about this fascinating and fast-paced area of research.

This book provides a state-of-the-art approach to the molecular basis of hematologic diseases and its translation into improved diagnostics and novel therapeutic strategies. Several representative hemato-oncologic malignancies are analyzed in detail: acute lymphoblastic leukemia, acute myeloid leukemia, B-cell Non-Hodgkin lymphomas, multiple myeloma, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Experts in the field describe the molecular methods applied for modern diagnostics and therapies, such as hematopoietic stem cell transplantation, donor recipient matching, banking of biological material, analyses of post-transplant chimerism, and minimal residual disease monitoring. The volume concludes with an extensive section comprising thorough step-by-step protocols of molecular techniques in hematology, all of them validated in the authors own laboratories.

"

This book highlights the unique aspects of oncologic ophthalmology as a medical and surgical discipline practiced at a comprehensive cancer center. Multi-disciplinary management of ocular, orbital and adnexal cancers are highlighted using simple and tried-and-true algorithms. In addition, ocular problems caused as a direct result of cancer treatment are reviewed using illustrative photographs and case presentations. The content is provided by full-time ophthalmology faculty and fellows at M. D. Anderson Cancer Center. Experts in complementary disciplines such as ophthalmic pathology, dermatopathology, radiation oncology, radiology, and other surgical subspecialties have brought their unique perspective to each chapter. The book is abundant with clinical photographs as well as interesting case presentations that will help the clinician correctly diagnose cancers of the orbit, eye, and adnexal structures, initiate appropriate management, as well as recognize and treat common ocular complications of cancer therapy.

In this state-of-the-art exploration of a hugely dynamic and fast-evolving field of research, leading researchers share their collective wisdom on the role that stem cells could play in the context of physiological stress and lung injury. The text focuses on reviewing the most relevant-and recent-ideas on using local, endogenous, and exogenous progenitor/stem cells in preventing and treating injury to the lung. The lungs are one of the most complex organs in the human body, with a mature adult lung boasting at least 40 morphologically differentiated cell lineages. Our entire blood supply passes through the lung's alveolar units during oxygenation. This interaction with the outside world, along with the intricacies of its structure, makes the lung a highly susceptible organ that is vulnerable to numerous types of injury and infection. This means that the mechanisms of lung repair are in themselves correspondingly complex. Because of their multipotentiality, as well as the fact of the lung's relatively rapid cell turnover, stem cells are thought to be an important alternative cell-base therapy in lung injury. Despite the controversial nature of stem cell research, there has been growing interest in both local and endogenous stem cells in the lung. This highly topical book with chapters on everything from using mesenchymal stem cells in lung repair to the effect of physical activity on the mobilization of stem and progenitor cells, represents an exciting body of work by outstanding investigators and will be required reading for those with an interest in the subject.

This volume explores various approaches for enrichment, detection, isolation, and molecular profiling of circulating tumor cells (CTCs). Each chapter provides comprehensive descriptions and guidelines on how to perform innovative experiments in CTC research. Included are protocols for capture of CTCs via filtration and density gradient centrifugation; microfluidic and immunomagnetic separation of CTCs; detection of CTCs by immunocytochemistry, fluorescence in situ hybridization, and flow cytometry; assays designed for genomic characterization and functional analyses of CTCs, and many more. Written in the highly successful Methods in Molecular Biology series format, the chapters in this book include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and authoritative, Circula ting Tumor Cells: Methods and Protocols is a valuable resource for laboratory researchers and clinicians who are interested in furthering their studies on CTCs.

This unique book focuses on the non-myeloma plasma cell dyscrasias. A key resource for this group of diseases, the book features the latest in emerging knowledge and therapeutic developments, including novel therapies. Each disease-specific chapter discusses biology, disease course, and appropriate therapeutic interventions, covering plasma cell leukemia, plasmacytoma, POEMS Syndrome and Castleman's Disease, Waldenstroem macroglobulinemia, immunoglobin deposition disease, and cryoglobulinemic syndromes, among others. The only book dedicated to this intriguing family of diseases, Biology and Management of Unusual Plasma Cell Dyscrasias will be a long-lasting reference for clinicians and scientists alike.

Cytogenetic studies of malignancy have become an essential tool in the clinical management of cancer patients. Cancer Cytogenetics: Methods and Protocols presents eminently practical key cytogenetic and FISH techniques for every stage of diagnostic service. Experts in the field describe detailed cytogenetic analysis methods, fluorescence in situ hybridization and array methods currently being applied to investigate and diagnose different varieties of cancer. Written in the highly successful Methods in Molecular Biology series format, chapters contain introductions to their respective topics, lists of the necessary materials and reagents, and step-by-step, readily reproducible laboratory protocols. The authors of the various chapters have also provided extensive notes to guide individuals who are new to these methods through the pitfalls that bedevil all such testing.

Authoritative and accessible, Cancer Cytogenetics: Methods and Protocols serves as an ideal guide to scientists of all backgrounds, allowing them to either establish new techniques in their laboratories or find the different variations of standard methods helpful in improving their results.

"Alison, I’ve got bad news."

The voice of the pathologist at the other end of the telephone confirmed for Alison Tucker the news no woman ever wants to hear: she had breast cancer. Once the shock had settled, Alison decided that she would take charge. Not only would she take ownership of the dreaded disease, but she would do so with a positive mindset and prepare herself as best she could for what was to come. She did detailed research and paid close heed to what she was told by others who had walked the path before her. As she navigated her way through surgery and the chemotherapy and radiotherapy that followed, Alison’s determination paid off. Not only did she make new friends, but she learnt valuable life lessons too: acceptance of the illness for what it was, the amazing impact of ongoing advances in medical science, and the importance of being able to ask for – and receive – help.

In My Best Worst Year – A Breast Cancer Story, Alison gives us an authentic account of her experience, offering insights and advice for others who might one day face the same diagnosis. You will accompany her on her highs, empathise with her lows, and be amused by humorous anecdotes along the way. Through the generous support of family and friends, she has amassed a collection of practical tips for both patients and supporters which she shares with open-hearted honesty:

• What to take to chemotherapy sessions
• What to look for when choosing a wig
• What side effects a person can expect when having the various types of cancer treatment
• What to say, and what not to say, to a cancer patient
• How to remove stress from a cancer patient’s life
• What kind of gifts and gestures are most appreciated

Contrary to Alison’s expectations, her year of treatment turned out to be her best worst year. By telling her story, she underlines the importance of a positive attitude and hopes to show that a person can still lead a productive and enjoyable life even after being diagnosed with cancer.

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.